American Capital Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
VCM
VPM
American Capital Advisory's VRTX Position: Q1 2026 in Review
American Capital Advisory increased its Vertex Pharmaceuticals (VRTX) stake by 43% in Q1 2026, buying an estimated $1.4K and bringing the position to 10 shares worth $4.47K. The position accounts for ﹤0.01% of the portfolio, ranked #410.
American Capital Advisory first reported a position in VRTX in Q1 2025 and has held it in 5 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- American Capital Advisory held 10 shares of Vertex Pharmaceuticals worth $4.47K as of Q1 2026.
- American Capital Advisory bought 3 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.4K.
- Vertex Pharmaceuticals made up ﹤0.01% of American Capital Advisory's portfolio in Q1 2026, its #410 holding.
- American Capital Advisory first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on American Capital Advisory's 13F filing for Q1 2026, filed 29 Apr 2026.